Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synthetic pure cannabidiol with temozolomide, with or without clomiphene, for recurrent or progressive glioblastoma
MOH_2021-10-19_010337Phase 2Not yet recruiting
- Sponsor
- Enveric Biosciences
- Start
- Apr 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cannabidiol, clomiphene and temozolomide in glioblastoma (GBM) (6 arms), sponsored by Enveric Biosciences. Primary endpoints: Safety of synthetic pure cannabidiol with temozolomide, with or without clomiphene, Maximum tolerated dose of cannabidiol and 1 more. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
cannabidiolclomiphenetemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on MOH_2021-10-19_010337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-19_010337.